"Ko\u010Dka, Viktor" . . . "Bedn\u00E1\u0159, Franti\u0161ek" . . "CZ - \u010Cesk\u00E1 republika" . "Ulman, Jaroslav" . . "Cor et Vasa" . "[1A582B1F519A]" . "L\u00EDnkov\u00E1, Hana" . . . "266232" . "Tou\u0161ek, Petr" . "7"^^ . "Straka, Zbyn\u011Bk" . "Aortic stenosis is the most common type of valvular heart disease in adulthood and transcatheter aortic valve implantation (TAVI) is a new, evolving alternative to standard surgical aortic valve replacement, suitable for high surgical risk patients. We present our initial experience with this method. The third generation of a self expanding CoreValve Revalving 18 Fr. valve is made up of a nitinol frame and a bioprosthetic valve from the porcine pericardium. We describe the course of the procedure step by step. From April 2009 to January 2010, we performed the TAVI procedure in 17 patients with severe symptomatic aortic stenoses. Brief cohort characteristics are as follows (mean values): age 81 years, logistic EuroSCORE 21%, aortic valve area index 0.42 cm2/m2, left ventricular ejection fraction 52%. The procedural success rate was 100%. Thirty-day mortality was 0% and clinical improvement was obvious, with dyspnea improving by at least one NYHA class in all patients. Our initial experience with TAVI i"@en . "Aortic stenosis; Transcatheter aortic valve implantation"@en . . . "11"^^ . . . "Aort\u00E1ln\u00ED sten\u00F3za je nej\u010Dast\u011Bj\u0161\u00ED chlopenn\u00ED vadou v dosp\u011Blosti a katetriza\u010Dn\u00ED implantace aort\u00E1ln\u00ED chlopn\u011B (TAVI) je novou, rozv\u00EDjej\u00EDc\u00ED se alternativou ke standardn\u00ED chirurgick\u00E9 n\u00E1hrad\u011B aort\u00E1ln\u00ED chlopn\u011B (AVR), vhodnou pro pacienty s vysok\u00FDm opera\u010Dn\u00EDm rizikem. Shrnujeme prvn\u00ED zku\u0161enosti s touto metodou na na\u0161em pracovi\u0161ti. Autoexpandibiln\u00ED chlope\u0148 CoreValve Revalving 18 F 3. generace je tvo\u0159ena nitinolov\u00FDm r\u00E1mem a bioprot\u00E9zou z prase\u010D\u00EDho perikardu. P\u0159ehledn\u011B popisujeme pr\u016Fb\u011Bh v\u00FDkonu. Od dubna 2009 do ledna 2010 jsme TAVI provedli u 17 nemocn\u00FDch se symptomatickou v\u00FDznamnou aort\u00E1ln\u00ED sten\u00F3zou. Stru\u010Dn\u00E1 charakteristika souboru (pr\u016Fm\u011Brn\u00E9 hodnoty): v\u011Bk 81 let, logistick\u00E9 EuroSCORE 21%, plocha aort\u00E1ln\u00EDho \u00FAst\u00ED 0,42 cm2/m2, ejek\u010Dn\u00ED frakce LK 52%. Technick\u00E1 \u00FAsp\u011B\u0161nost v\u00FDkonu byla 100%. Mortalita do 30 dn\u016F byla 0% a byl jasn\u011B patrn\u00FD p\u0159\u00EDzniv\u00FD vliv TAVI na symptomatologii nemocn\u00FDch - du\u0161nost se zlep\u0161ila alespo\u0148 o jeden stupe\u0148 NYHA klasifikace u v\u0161ech nemocn\u00FDch. Na\u0161e prvn\u00ED zku\u0161enosti s TAVI jsou velmi povzbudiv\u00E9. \u00DAsp\u011Bch"@cs . "52" . "0010-8650" . "Katetriza\u010Dn\u00ED implantace aort\u00E1ln\u00ED chlopn\u011B (TAVI) typu CoreValve - prvn\u00ED zku\u0161enosti ve FNKV, v\u00FDhody a \u00FAskal\u00ED nov\u00E9 metody" . "RIV/00216208:11120/10:00002572" . "Transcatheter aortic valve implantation (TAVI) using the CoreValve prosthesis - initial experience in Kr\u00E1lovsk\u00E9 Vinohrady University Hospital, advantages and pitfalls of the new method"@en . "6"^^ . . "11120" . . . . "Katetriza\u010Dn\u00ED implantace aort\u00E1ln\u00ED chlopn\u011B (TAVI) typu CoreValve - prvn\u00ED zku\u0161enosti ve FNKV, v\u00FDhody a \u00FAskal\u00ED nov\u00E9 metody" . "Katetriza\u010Dn\u00ED implantace aort\u00E1ln\u00ED chlopn\u011B (TAVI) typu CoreValve - prvn\u00ED zku\u0161enosti ve FNKV, v\u00FDhody a \u00FAskal\u00ED nov\u00E9 metody"@cs . "Katetriza\u010Dn\u00ED implantace aort\u00E1ln\u00ED chlopn\u011B (TAVI) typu CoreValve - prvn\u00ED zku\u0161enosti ve FNKV, v\u00FDhody a \u00FAskal\u00ED nov\u00E9 metody"@cs . . . "Suppl. 1" . . "Widimsk\u00FD, Petr" . "Transcatheter aortic valve implantation (TAVI) using the CoreValve prosthesis - initial experience in Kr\u00E1lovsk\u00E9 Vinohrady University Hospital, advantages and pitfalls of the new method"@en . "RIV/00216208:11120/10:00002572!RIV11-MSM-11120___" . "Z(MSM0021620817)" . . . . "Aort\u00E1ln\u00ED sten\u00F3za je nej\u010Dast\u011Bj\u0161\u00ED chlopenn\u00ED vadou v dosp\u011Blosti a katetriza\u010Dn\u00ED implantace aort\u00E1ln\u00ED chlopn\u011B (TAVI) je novou, rozv\u00EDjej\u00EDc\u00ED se alternativou ke standardn\u00ED chirurgick\u00E9 n\u00E1hrad\u011B aort\u00E1ln\u00ED chlopn\u011B (AVR), vhodnou pro pacienty s vysok\u00FDm opera\u010Dn\u00EDm rizikem. Shrnujeme prvn\u00ED zku\u0161enosti s touto metodou na na\u0161em pracovi\u0161ti. Autoexpandibiln\u00ED chlope\u0148 CoreValve Revalving 18 F 3. generace je tvo\u0159ena nitinolov\u00FDm r\u00E1mem a bioprot\u00E9zou z prase\u010D\u00EDho perikardu. P\u0159ehledn\u011B popisujeme pr\u016Fb\u011Bh v\u00FDkonu. Od dubna 2009 do ledna 2010 jsme TAVI provedli u 17 nemocn\u00FDch se symptomatickou v\u00FDznamnou aort\u00E1ln\u00ED sten\u00F3zou. Stru\u010Dn\u00E1 charakteristika souboru (pr\u016Fm\u011Brn\u00E9 hodnoty): v\u011Bk 81 let, logistick\u00E9 EuroSCORE 21%, plocha aort\u00E1ln\u00EDho \u00FAst\u00ED 0,42 cm2/m2, ejek\u010Dn\u00ED frakce LK 52%. Technick\u00E1 \u00FAsp\u011B\u0161nost v\u00FDkonu byla 100%. Mortalita do 30 dn\u016F byla 0% a byl jasn\u011B patrn\u00FD p\u0159\u00EDzniv\u00FD vliv TAVI na symptomatologii nemocn\u00FDch - du\u0161nost se zlep\u0161ila alespo\u0148 o jeden stupe\u0148 NYHA klasifikace u v\u0161ech nemocn\u00FDch. Na\u0161e prvn\u00ED zku\u0161enosti s TAVI jsou velmi povzbudiv\u00E9. \u00DAsp\u011Bch" .